BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 32519553)

  • 1. Effect of co-treatment with doxorubicin and verapamil loaded into chitosan nanoparticles on diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Abo Mansour HE; El-Batsh MM; Badawy NS; Mehanna ET; Mesbah NM; Abo-Elmatty DM
    Hum Exp Toxicol; 2020 Nov; 39(11):1528-1544. PubMed ID: 32519553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
    Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ginger Extract Loaded into Chitosan Nanoparticles Enhances Cytotoxicity and Reduces Cardiotoxicity of Doxorubicin in Hepatocellular Carcinoma in Mice.
    Abo Mansour HE; El-Batsh MM; Badawy NS; Mehanna ET; Mesbah NM; Abo-Elmatty DM
    Nutr Cancer; 2021; 73(11-12):2347-2362. PubMed ID: 32972241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance.
    Wang C; Wei X; Shao G
    Med Sci Monit; 2021 Feb; 27():e927727. PubMed ID: 33524008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chitosan-g-TPGS nanoparticles for anticancer drug delivery and overcoming multidrug resistance.
    Guo Y; Chu M; Tan S; Zhao S; Liu H; Otieno BO; Yang X; Xu C; Zhang Z
    Mol Pharm; 2014 Jan; 11(1):59-70. PubMed ID: 24229050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced anticancer effect and reduced toxicity of doxorubicin in combination with thymoquinone released from poly-N-acetyl glucosamine nanomatrix in mice bearing solid Ehrlish carcinoma.
    El-Ashmawy NE; Khedr EG; Ebeid EM; Salem ML; Zidan AA; Mosalam EM
    Eur J Pharm Sci; 2017 Nov; 109():525-532. PubMed ID: 28890201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver cancer targeting of Doxorubicin with reduced distribution to the heart using hematoporphyrin-modified albumin nanoparticles in rats.
    Chang JE; Shim WS; Yang SG; Kwak EY; Chong S; Kim DD; Chung SJ; Shim CK
    Pharm Res; 2012 Mar; 29(3):795-805. PubMed ID: 21971829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy.
    Zhu QL; Zhou Y; Guan M; Zhou XF; Yang SD; Liu Y; Chen WL; Zhang CG; Yuan ZQ; Liu C; Zhu AJ; Zhang XN
    Biomaterials; 2014 Jul; 35(22):5965-76. PubMed ID: 24768047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.
    Pranatharthiharan S; Patel MD; Malshe VC; Pujari V; Gorakshakar A; Madkaikar M; Ghosh K; Devarajan PV
    Drug Deliv; 2017 Nov; 24(1):20-29. PubMed ID: 28155331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation of a multifunctional verapamil-loaded nano-carrier based on a self-assembling PEGylated prodrug.
    Zhao D; Liu N; Shi K; Wang X; Wu G
    Colloids Surf B Biointerfaces; 2015 Nov; 135():682-688. PubMed ID: 26340357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-375 delivered by lipid-coated doxorubicin-calcium carbonate nanoparticles overcomes chemoresistance in hepatocellular carcinoma.
    Zhao P; Wu S; Cheng Y; You J; Chen Y; Li M; He C; Zhang X; Yang T; Lu Y; Lee RJ; He X; Xiang G
    Nanomedicine; 2017 Nov; 13(8):2507-2516. PubMed ID: 28577837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice.
    Nasr M; Nafee N; Saad H; Kazem A
    Eur J Pharm Biopharm; 2014 Sep; 88(1):216-25. PubMed ID: 24813390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrolide antibiotics differentially influence human HepG2 cytotoxicity and modulate intrinsic/extrinsic apoptotic pathways in rat hepatocellular carcinoma model.
    Abdel-Hamid NI; El-Azab MF; Moustafa YM
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Apr; 390(4):379-395. PubMed ID: 28070612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel self-assembly albumin nanocarrier for reducing doxorubicin-mediated cardiotoxicity.
    Yuan A; Wu J; Song C; Tang X; Qiao Q; Zhao L; Gong G; Hu Y
    J Pharm Sci; 2013 May; 102(5):1626-35. PubMed ID: 23423631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Negative-charge-functionalized mesoporous silica nanoparticles as drug vehicles targeting hepatocellular carcinoma.
    Xie M; Xu Y; Shen H; Shen S; Ge Y; Xie J
    Int J Pharm; 2014 Oct; 474(1-2):223-31. PubMed ID: 25149125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chitosan-coated doxorubicin nano-particles drug delivery system inhibits cell growth of liver cancer via p53/PRC1 pathway.
    Ye BL; Zheng R; Ruan XJ; Zheng ZH; Cai HJ
    Biochem Biophys Res Commun; 2018 Jan; 495(1):414-420. PubMed ID: 29097204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma.
    Xue H; Yu Z; Liu Y; Yuan W; Yang T; You J; He X; Lee RJ; Li L; Xu C
    Int J Nanomedicine; 2017; 12():5271-5287. PubMed ID: 28769563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Codelivery of doxorubicin and elacridar to target both liver cancer cells and stem cells by polylactide-co-glycolide/d-alpha-tocopherol polyethylene glycol 1000 succinate nanoparticles.
    Chen D; Pan X; Xie F; Lu Y; Zou H; Yin C; Zhang Y; Gao J
    Int J Nanomedicine; 2018; 13():6855-6870. PubMed ID: 30498347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of PLGA nanoparticles simultaneously loaded with vincristine and verapamil for treatment of hepatocellular carcinoma.
    Song XR; Zheng Y; He G; Yang L; Luo YF; He ZY; Li SZ; Li JM; Yu S; Luo X; Hou SX; Wei YQ
    J Pharm Sci; 2010 Dec; 99(12):4874-9. PubMed ID: 20821385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma.
    Zhou X; Zhang M; Yung B; Li H; Zhou C; Lee LJ; Lee RJ
    Int J Nanomedicine; 2012; 7():5465-74. PubMed ID: 23093902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.